<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185441</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0119 - TANZÂNIA</org_study_id>
    <nct_id>NCT04185441</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia</brief_title>
  <official_title>National, Multicenter, Randomized, Double-blind, Double-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Tanzânia association in
      adults with erectile dysfunction associated with Benign Prostatic Hyperplasia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in erectile function questionnaire.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The erectile function questionnaire score ranges from 1 to 30 points. The lower the score, the higher the degree of erectile dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>TANZÂNIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is double-dummy. The patient must take 2 pills, as follow:
1 capsule Tanzânia association, oral, once a day, and
1 tablet tamsulosin placebo, oral, once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omnic Ocas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is double-dummy. The patient must take 2 pills, as follow:
1 tablet Omnic Ocas, oral, once a day, and
1 capsule Tanzânia association placebo, oral, once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tanzânia association</intervention_name>
    <description>Tanzânia association capsule</description>
    <arm_group_label>TANZÂNIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omnic Ocas</intervention_name>
    <description>Tamsulosin 0,4 mg</description>
    <arm_group_label>Omnic Ocas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Omnic Ocas placebo</intervention_name>
    <description>Tamsulosin placebo</description>
    <arm_group_label>TANZÂNIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tanzânia association placebo</intervention_name>
    <description>EMS association placebo</description>
    <arm_group_label>Omnic Ocas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to confirm voluntary participation and agree to all trial purposes by signing
             and dating the informed consent forms;

          -  Male participants aged 18 years or more;

          -  Sexually active participants with a defined partner who have averaged 1 attempt at
             sexual intercourse per week in the past month;

          -  Diagnosis of Benign Prostatic Hyperplasia;

          -  Diagnosis of erectile dysfunction;

          -  Patients with score between 6 and 25 points in the erectile function questionnaire;

          -  IPSS (International Prostate Symptom Score) greater or equal to 8 points;

        Exclusion Criteria:

          -  Known hypersensitivity to the formula components used during the clinical trial;

          -  History of alcohol and/or substance abuse within 2 years;

          -  Diagnosis of other diseases or conditions in the urinary tract, including but not
             limited to: cancer, neurogenic bladder; urinary incontinence, recurrent infection,
             urethral stricture, bacterial prostatitis;

          -  Clinical evidence of prostate cancer;

          -  Hypogonadism or absent sexual desire;

          -  Severe psychiatric or psychosocial disorders;

          -  Primary erectile dysfunction;

          -  Polyneuropathy, neurodegenerative diseases, trauma or spinal cord injuries, central
             nervous system tumors or other conditions that may affect erections;

          -  Anatomical penile deformation that can significantly impair erection, including but
             not limited to: angulation, cavernous fibrosis, Peyronie's disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

